Gain Therapeutics, Inc. (NASDAQ:GANX – Get Free Report) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 182,400 shares, a decline of 9.5% from the October 15th total of 201,600 shares. Based on an average daily volume of 37,600 shares, the short-interest ratio is presently 4.9 days. Currently, 1.8% of the company’s shares are short sold.
Gain Therapeutics Stock Performance
NASDAQ GANX opened at $2.90 on Thursday. Gain Therapeutics has a 1 year low of $2.56 and a 1 year high of $6.19. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.10 and a quick ratio of 3.10. The stock has a market capitalization of $36.83 million, a PE ratio of -1.59 and a beta of 0.35. The company’s 50 day simple moving average is $3.17 and its two-hundred day simple moving average is $3.96.
Analyst Ratings Changes
GANX has been the topic of a number of research analyst reports. Maxim Group started coverage on shares of Gain Therapeutics in a research report on Tuesday, September 12th. They set a “buy” rating and a $10.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a report on Monday, September 18th. Finally, Chardan Capital restated a “buy” rating and issued a $6.00 target price on shares of Gain Therapeutics in a report on Monday, August 14th.
Institutional Investors Weigh In On Gain Therapeutics
Large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP purchased a new position in Gain Therapeutics in the third quarter worth about $39,000. Jane Street Group LLC purchased a new position in Gain Therapeutics in the first quarter worth about $48,000. NewEdge Advisors LLC purchased a new position in shares of Gain Therapeutics during the first quarter valued at approximately $54,000. Susquehanna International Group LLP purchased a new position in shares of Gain Therapeutics during the first quarter valued at approximately $73,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Gain Therapeutics during the second quarter valued at approximately $119,000. Institutional investors own 9.99% of the company’s stock.
About Gain Therapeutics
Gain Therapeutics, Inc, a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease.
- Five stocks we like better than Gain Therapeutics
- Most Volatile Stocks, What Investors Need to Know
- 3 value stocks you shouldn’t let go of this quarter
- When to Sell a Stock for Profit or Loss
- 5 must-have next-gen technologies that institutions are buying
- Are Penny Stocks a Good Fit for Your Portfolio?
- 3 intriguing late-week earnings plays for short-term traders
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.